0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessKAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synthetic antimalarial spiroindolone analogue with potent, dose-dependent antimalarial activity against asexual and sexual stages of Plasmodium falciparum.
Sir Nicholas White, Sasithon Pukrittayakamee, Aung Pyae Phyo, Ronnatrai Rueangweerayut, François Nosten, Podjanee Jittamala, Atthanee Jeeyapant, Jay Prakash Jain, Gilbert Lefèvre, Ruobing Li, Baldur Magnusson, Thierry T. Diagana, F. Joel Leong (2014). Spiroindolone KAE609 for Falciparum and Vivax Malaria. New England Journal of Medicine, 371(5), pp. 403-410, DOI: 10.1056/nejmoa1315860.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2014
Authors
13
Datasets
0
Total Files
0
Language
English
Journal
New England Journal of Medicine
DOI
10.1056/nejmoa1315860
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
